Treatment with biologics of patients with inflammatory joint diseases

Over the past two decades, biologics (Bs) have been widely used in the treatment of patients with inflammatory joint diseases (IJD). The treatment of IJD aims at reducing disease progression, improving patients’ physical health and well-being, and achieving long-lasting remission or, at least, minimal disease activity. The introduction of Bs in rheumatology practice has significantly improved patients’ outcomes and prognosis. Their use, however, involves undertaking significant risks and challenges for both patients and medical teams. The purpose of this article is to provide a brief overview of the biological therapies currently approved for this group of diseases in Bulgaria and the indications for administration and monitoring of the most common side effects. The optimal administration of Bs is determined by treatment efficacy, discussion of benefits and risks, prevention of the possible development of severe adverse effects, administration regimens, and routes of administration of Bs. The analysis of major issues during treatment helps summarize the information on the use of Bs, thus increasing the possibility of managing the risks associated with their use by strengthening the engagement of healthcare experts and patients in the process of monitoring the impact of biological agents.